Correction to: Quality of Life Research (2023) 32:989–1003 https://doi.org/10.1007/s11136-022-03327-4
In the original publication of the article, the authors realized that the scores of two dimensions of the EORTC QLQ BR23 (Sexual Function and Sexual Enjoyment) were wrongly reversed while preparing the tables. This mistake affects two lines (Sexual Function and Sexual Enjoyment) of Table 4 and Supplementary Table (1.3.2, 1.3.3, 2.3.2 and 2.3.3). The correct version of Table 4 and the supplementary information are provided in this correction.
Table 4
Mean scores and standard deviations of EORTC QLQ-BR-23 according to age, Charlson Comorbidity Index, and stage
All | Age | Comorbidity index | Tumor stage | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
< 40 | 40–65 | > 65 | p value* | 0 | ≥ 1 | p value* | 0 | I | II | III | p value* | ||
At diagnosis | |||||||||||||
Body Image | 92.3 (16.7) | 87.5 (20.8) | 92.0 (17.0) | 94.5 (14.4) | 0.003 | 92.4 (16.3) | 92.1 (18.4) | 0.779 | 94.2 (12.6) | 92.6 (16.7) | 91.9 (17.2) | 89.8 (19.8) | 0.258 |
Sexual Function | 23.5 (26.1) | 31.3 (27.1) | 27.4 (26.6) | 10.6 (19.2) | < 0.001 | 24.9 (25.8) | 18.2 (26.5) | < 0.001 | 24.7 (26.5) | 24.9 (26.1) | 21.1 (25.4) | 21.8 (28.3) | 0.126 |
Sexual enjoy | 54.6 (29.1) | 59.4 (32.1) | 56.2 (28.8) | 42.5 (26.1) | < 0.001 | 55.3 (28.9) | 50.5 (29.9) | 0.140 | 54.5 (26.6) | 54.8 (28.3) | 53.6 (29.7) | 57 (36.0) | 0.913 |
Future perspective | 45.9 (31.9) | 36.4 (32.0) | 45.7 (31.7) | 48.8 (32.2) | 0.009 | 45.8 (31.3) | 46.3 (34.2) | 0.822 | 50.3 (29.9) | 45.8 (32.1) | 46.4 (32.4) | 39.2 (31.3) | 0.090 |
Systemic therapy effects | 12.5 (13.9) | 11.5 (13.9) | 12.7 (14.4) | 12.4 (12.7) | 0.764 | 12.2 (13.8) | 13.6 (14.3) | 0.169 | 12.6 (13.5) | 11.8 (13.2) | 13.2 (14.8) | 14.4 (16.2) | 0.235 |
Breast symptoms | 13.2 (16.9) | 19.2 (20.4) | 13.4 (16.9) | 11.1 (15.8) | 0.001 | 13.7 (17.2) | 11.0 (15.6) | 0.021 | 13.4 (17.2) | 12.5 (17.2) | 14.4 (16.7) | 12.9 (15.8) | 0.342 |
Arm symptoms | 8.7 (15.6) | 6.4 (12.5) | 8.4 (14.7) | 10.0 (18.3) | 0.127 | 8.2 (14.7) | 11.0 (18.5) | 0.011 | 7.8 (14.0) | 8.4 (15.5) | 9.6 (15.8) | 8.6 (17.2) | 0.592 |
Upset hair loss | 24.0 (31.6) | 12.3 (27.7) | 25.6 (33.2) | 23.6 (27.7) | 0.223 | 23.5 (31.4) | 26.7 (33.1) | 0.564 | 11.1 (18.5) | 22.9 (32.8) | 28.6 (32.5) | 33.3 (31.2) | 0.053 |
At 2-year follow-up | |||||||||||||
Body Image | 84.6 (24.6) | 79.7 (28.6) | 82.9 (25.8) | 88.8 (21.0) | 0.001 | 84.6 (24.7) | 84.7 (24.4) | 0.956 | 90.1 (18.3) | 86.7 (22.4) | 81.4 (27.0) | 73.5 (33.7) | < 0.001 |
Sexual Function | 20.9 (23.5) | 29.5 (21.0) | 25 (24.1) | 9.9 (17.9) | < 0.001 | 22.4 (24.0) | 15.4 (21.0) | < 0.001 | 23.8 (24.1) | 21.7 (24.3) | 18.9 (22.5) | 19 (19.8) | 0.163 |
Sexual enjoy | 50.3 (27.8) | 62.8 (23.7) | 53.2 (27.0) | 34.3 (27.1) | < 0.001 | 51.3 (28.1) | 45.6 (26.2) | 0.070 | 52.8 (26.3) | 51.3 (29.2) | 48.2 (27.1) | 47 (22.6) | 0.518 |
Future perspective | 59.5 (32.1) | 55.9 (37.4) | 57.1 (31.9) | 65.0 (31.4) | 0.001 | 59.2 (31.9) | 60.6 (33.0) | 0.557 | 66.4 (29.3) | 59.6 (31.6) | 59.1 (32.4) | 48.4 (36.9) | 0.003 |
Systemic therapy effects | 18.3 (16.5) | 12.2 (11.1) | 18.9 (16.8) | 17.9 (16.1) | 0.056 | 17.7 (16.3) | 20.7 (17.3) | 0.014 | 16.6 (15.4) | 17.8 (15.8) | 19.3 (17.8) | 21.1 (17.8) | 0.171 |
Breast symptoms | 16.0 (17.8) | 17.4 (19.5) | 17.4 (18.0) | 13.0 (16.9) | 0.001 | 15.8 (16.8) | 16.6 (21.0) | 0.572 | 15.0 (18.5) | 16.0 (17.0) | 16.1 (18.7) | 17.2 (18.5) | 0.859 |
Arm symptoms | 15.7 (20.3) | 9.5 (15.0) | 16.2 (20.3) | 15.5 (20.8) | 0.157 | 15.0 (19.5) | 18.2 (23.0) | 0.035 | 12.0 (18.0) | 14.2 (19.4) | 18.2 (21.0) | 22.8 (24.8) | < 0.001 |
Upset hair loss | 31.1 (33.7) | 13.9 (30.0) | 32.0 (33.4) | 31.2 (34.3) | 0.192 | 29.4 (32.6) | 36.9 (36.7) | 0.058 | 22.0 (26.8) | 29.8 (33.4) | 34.4 (34.5) | 42.0 (40.5) | 0.066 |
The original article has been corrected.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.